Quote:

---

we have prepared a rollover protocol to ensure that CRC patients who remain stable can continue leronlimab treatment beyond 48 weeks and to allow patients with disease progression the opportunity to receive leronlimab at a dose of 700 mg in combination with an ICI.

---

Yes, the writing above is unclear -- hard to tell whether BOTH "patients who remain stable" and "patients with disease progression" are covered by the modifier "beyond 48 weeks." Is the "Opportunity to receive Leron" also after 48 weeks, or immediately?

However, as I remember it Katangolo asked Dr. Weinberg that very question at the ESMO gastrointestinal conference last year, and the answer was: after 48 weeks. Unfortunately.

Katangolo can correct me if I'm wrong.